Objective: Nationwide initiatives have promoted greater adoption of health information technology as a means to reduce adverse drug events (ADEs). Hospital adoption of electronic health records with Meaningful Use (MU) capabilities expected to improve medication safety has grown rapidly. However, evidence that MU capabilities are associated with declines in in-hospital ADEs is lacking. 
eligible professionals and hospitals can receive financial incentives for adoption and Meaningful Use (MU) of interoperable EHRs. To meet MU requirements, hospitals are required to adopt specific MU capabilities (eg, CPOE) expected to reduce errors and promote safer care. 5 Since passage of HITECH in 2009, hospital adoption of EHRs has grown rapidly. 6 MU incentives were initiated in 2011, and by 2013, 83% of hospitals had attested to having MU capabilities for stage 1 of the 3-stage MU program. 7 Concurrent with MU uptake, national reports indicate that patient safety has been improving in US hospitals. From 2010 to 2013, rates of hospital-acquired conditions reported on the Agency for Healthcare Research and Quality's (AHRQ) National Scorecard declined by 17%, including a reduction in the prevalence of in-hospital ADEs. 8 Although it is believed that health IT was a contributing factor, evidence that MU played a contributing role in the decline in ADEs is lacking.
In this study, we sought to answer 4 questions. First, how have rates of in-hospital ADEs and hospital adoption of medication-related MU capabilities changed from 2010 to 2013? Second, to what extent is adoption of MU capabilities associated with occurrence of ADEs? Third, does this relationship depend on experience with MU capabilities and interoperability status? Fourth, how much of the reduction in ADEs from 2010 to 2013 can be attributed to adoption of MU capabilities?
METHODS

Data
We used data on in-hospital ADEs from 2010 to 2013 from the Medicare Patient Safety Monitoring System (MPSMS). The MPSMS is a nationwide surveillance system designed to track rates of adverse events occurring in hospitalized patients. 9 Starting in 2010, MPSMS has been the main data source for reporting national estimates of hospital-acquired conditions on the AHRQ National Scorecard. The MPSMS identifies the occurrence of 21 adverse events, including ADEs, through medical record abstraction conducted by the Centers for Medicare and Medicaid Services Clinical Data Abstraction Center. 10 The MPSMS sample was derived from the Hospital Inpatient Quality Reporting Program and was limited to adults 18 and older hospitalized for 4 medical condition groups: acute myocardial infarction (AMI), heart failure (HF), pneumonia, and conditions requiring major surgery, which represent about one-quarter of all inpatient hospitalizations each year. The hospital sample was based on a rotating random sample from Inpatient Quality Reporting and included around 1400 hospitals in 2010 (n ¼ 1385) and 2011 (n ¼ 1384) and around 1100 hospitals in 2012 (n ¼ 1095); however, the sample decreased to around 700 hospitals in 2013 (n ¼ 726) but allowed for reporting of national trends. MPSMS data included variables for exposure to and occurrence of ADEs, patient characteristics, and hospital identifiers. We used data on MU capabilities and interoperability from the 2008 to 2013 HIMSS Analytics Database (HAD). Updated on a rolling basis, the HAD captures information on hospital adoption of specific EHR functionalities and interoperability. To assess the maturity of a hospital's EHR system, HIMSS Analytics developed the Electronic Medical Record Adoption Model (EMRAM) based on a proprietary scoring methodology applied to the HAD. EMRAM has been validated by industry experts and is widely used to benchmark hospitals in the United States and abroad.
11 EMRAM scores and hospital identifiers were obtained from HIMSS Analytics. We used data on hospital characteristics from the 2010 to 2013 American Hospital Association Annual Survey Database.
Adverse drug events
Our measure of in-hospital ADEs was based on selected ADEs identified through chart abstraction. The MPSMS identifies 5 ADEs associated with the following high-risk drugs: (1) hypoglycemic agents (insulin, oral hypoglycemic, combination of both), (2) lowmolecular-weight heparin and factor Xa inhibitors, (3) intravenous heparin, (4) warfarin, and (5) digoxin. MPSMS uses explicit chart review algorithms to identify a patient's exposure to these drugs and the actual occurrence of an adverse event linked to them during hospitalization. 12 For example, an anticoagulant-related ADE is identified by the following: drug exposure, evidence of a trigger that identifies a drug-related problem (eg, abrupt cessation of warfarin, international normalized ratio !4, or administration of vitamin K), and evidence of an injury to the patient (eg, bleeding, death, treatment for cardiac arrest, hematocrit drop of !3 points). The ADE measure is a dichotomous variable that is equal to 1 when an ADE associated with the specific drug exposure is identified in the hospital records. We used variables in MPSMS data reporting the occurrence of any of the 5 ADEs, conditional on exposure. These 5 measures are the only ADE measures used annually on the AHRQ National Scorecard. 
Medication-related meaningful use capabilities
Experience with MU capabilities
Our measure of experience with medication-related MU capabilities was based on the number of years at EMRAM stage 5. We used historical EMRAM data over a 3-year period (looking back from the current year), and we counted the number of years at stage 5 as a proxy for experience with MU capabilities. For each hospital-year, we created a categorical variable based on the number of years at stage 5, with categories for 3 or more years, 1-2 years, and 0 years.
Interoperability capability
Our measure of interoperability was based on achievement of EMRAM stage 7. Hospitals at stage 7 have a paperless EHR environment with the capability to exchange standardized transactions with all affiliated entities. HIMSS Analytics conducts formal site visits to validate that stage 7 hospitals have adopted all required capabilities. We used achievement of EMRAM stage 7 as a proxy for a hospital's adoption of interoperability capability within the organization. For each hospital-year, we created a variable for adoption of interoperability, with a value of 1 for achievement of stage 7 and 0 for achievement of less than stage 7.
Hospital and patient characteristics
Variables on hospital characteristics were derived from American Hospital Association data based on definitions used by the Healthcare Cost and Utilization Project. Hospital characteristics included bed size (small, medium, large), ownership type (nonprofit, forprofit, government), teaching hospital, rural location, and region (Northeast, Midwest, South, West).
We used variables on patient characteristics available in MPSMS data. Patient characteristics included age (<65, !65); gender (male, female); race (white, black, other); common clinical comorbidities, including history of cancer, cerebrovascular disease (CVD), chronic obstructive pulmonary disease, congestive heart failure (CHF), coronary artery disease (CAD), diabetes, obesity, or renal disease; and smoking status. We also included indicator variables for the 4 medical condition groups (AMI, HF, pneumonia, major surgery) in the MPSMS sample.
Sample
Our analytic sample was created by merging patient exposure-level MPSMS data with hospital-level EMRAM scores using hospital identifiers for each of the 4 years. Our unit of analysis was patient exposure, and we included patients who were exposed to more than 1 drug. We excluded a small number of MPSMS observations (n ¼ 4621) in hospitals unable to be matched with available EMRAM scores. Since the abstraction algorithm for ADE exposure required documentation of an overnight stay, we also excluded hospitalizations with reported length of stay <1 day (n ¼ 1806). The pooled sample included 110 789 patient exposures at risk for ADEs during inpatient stays in 2042 hospitals. After excluding cases with missing hospital characteristics, the final analytic sample included 110 052 patient exposures over the 4 years.
Analyses
For descriptive statistics, we calculated unweighted means for each variable-year of observation on the occurrence of ADEs and patient characteristics at the exposure level (Table 1) , and the prevalence of MU capabilities, experience, interoperability, and hospital characteristics at the hospital level (Table 2) .
To estimate the association of MU capabilities and occurrence of ADEs, we conducted univariate analyses with tests for equality of proportions and used a 2-level random intercept logistic regression model, adjusting for patient characteristics, hospital characteristics, and year of observation (Model 1). Similar models were used to analyze associations of ADEs and MU experience (Model 2) and interoperability (Model 3). The hospital-level intercept in our model was an additional control for unmeasured characteristics specific to each hospital. Since there were only 1.5 drug exposures per patient on average, we opted not to include a patient-level intercept in our model. All analyses were done using xtmelogit command in Stata/MP 13.1 (Stata Corp., College Station, TX, USA).
We used an epidemiological approach to estimate the contribution of MU capabilities to the reduction in total ADEs from 2010 to 2013. For total ADEs, we used previously reported national estimates of total ADEs in 2010 and 2013. 13 While based on the same MPSMS data used in this study, those estimates were extrapolated from 4 medical conditions to the inpatient population. For prevalence of MU capabilities, we used EMRAM scores to calculate the percent of patient exposures to MU capabilities in 2010 and 2013. We used our descriptive statistics for occurrence of ADEs and our regression model to estimate the relative risk of MU capabilities associated with occurrence of ADEs. The population-attributable risk fraction was used to determine the effect of changes in the prevalence of MU capabilities. 14 
RESULTS
Sample characteristics
The sample was generally evenly distributed across the 4 medical condition groups, with some variation in patient characteristics (Table 1 ). Patients exposed to the 5 drug categories had numerous comorbidities, including high rates of CAD, diabetes, CHF, and obesity. The distribution of comorbidities was similar each year, except for an increasing trend in obesity, renal disease, and smoking. The sample varied by key hospital characteristics ( Table 2 ). The majority of sample hospitals were nonprofit, nonteaching, located in urban areas, and of large or medium size. Most of the hospitals were located in the South and Midwest regions.
Occurrence of in-hospital ADEs
We found that the occurrence of in-hospital ADEs declined by 22% from 2010 to 2013 ( Table 1) . As of 2013, 6% of exposures resulted in an ADE during hospitalizations for the 4 medical condition groups studied.
Adoption of MU capabilities and interoperability
During this same period, hospital adoption of medication-related MU capabilities increased by 269% from 2010 to 2013 ( Table 2) . As of 2013, 44% of hospitals had adopted all 4 medication-related MU capabilities.
While adoption of interoperability more than doubled over this period, only 4% of hospitals had adopted MU capabilities and interoperability by 2013.
MU capabilities and occurrence of ADEs
Univariate analyses (Table 3 ) and regression results indicate that adoption of MU capabilities and interoperability was significantly associated with lower occurrence of in-hospital ADEs (Table 4) . MU capabilities were associated with 11% (95% CI, 0.84-0.96) lower odds of ADEs occurring, after adjusting for patient and hospital characteristics.
The association of MU capabilities and ADEs did not vary by experience with MU capabilities. We found no significant differences for !3 years with MU capabilities relative to 1-2 years since MU adoption (Table 4) .
Interoperability within the organization had the strongest relationship with occurrence of ADEs. Adoption of interoperability and MU capabilities was associated with 19% (95% CI, 0.67-0.98) lower odds of ADEs occurring (Table 4) .
Hospital characteristics associated with ADEs
Hospital size, ownership, teaching, and location were also associated with occurrence of ADEs (Table 4) . Large and medium-size hospitals had, respectively, 43% (95% CI, 1.33-1.54) and 19% (95% CI, 1.09-1.29) higher odds of ADEs occurring compared to small hospitals. Relative to nonprofit ownership, for-profit and government ownership were associated with, respectively, 16% (95% CI, 1.08-1.25) and 11% (95% CI, 1.02-1.20) higher odds of ADEs occurring. Teaching hospitals had 20% (95% CI, 1.12-1.28) higher odds than nonteaching hospitals. Rural location was associated with 22% (95% CI, 0.73-0.84) lower odds of ADEs occurring. Relative to the South region, the West and Midwest regions were associated with 9% (95% CI, 0.83-0.98) and 10% (95% confidence interval, 0.85-0.98) lower odds of ADEs occurring, respectively. 
Patient characteristics associated with ADEs
Patient age, race, comorbidities, and medical condition were associated with occurrence of ADEs (Table 4) . Age 65 or older was associated with 17% higher odds of ADEs occurring. Relative to whites, blacks and other races had 21% higher and 27% higher odds of ADEs occurring, respectively. History of renal disease, diabetes, CHF, CVD, or CAD had the greatest additional risk.
Contribution of Meaningful Use to reduction in ADEs
Based on prior national estimates from the AHRQ National Scorecard, 7 the prevalence of ADEs declined by 19% from 2010 to 2013, a reduction of 301 000 ADEs (Table 5 ). Over this same period, we found that the percent of exposure to ADEs in hospitals with adoption of MU capabilities increased by 258%. Overall, we calculated that 22% of the reduction in ADEs from 2010 to 2013 on the National Scorecard could be attributed to adoption of MU capabilities, or 67 000 ADEs averted by MU.
DISCUSSION
We found that the occurrence of in-hospital ADEs declined significantly from 2010 to 2013, a decline of 22%. Hospital adoption of medication-related MU capabilities was associated with 11% lower odds of ADEs occurring, but the effects did not vary by experience with MU. Interoperability capability was associated with 19% lower odds of ADEs occurring. Greater exposure to MU capabilities explained about one-fifth of the observed reduction in ADEs.
Our study provides evidence on the impact of HITECH investments on patient safety in US hospitals. Our findings are consistent with growing evidence on the impact of health IT on medication safety. Systematic reviews have concluded that specific MU capabilities, such as CPOE and BCMA, can significantly reduce ADEs in hospital settings. 15 Observational studies have found similar impacts of multifunctional EHRs on ADE rates using data from single states. 16, 17 Our study contributes to this literature by leveraging more recent national data and focusing on EHR functionalities required by MU stage 2. Apart from MU capabilities, some hospital and patient characteristics were associated with occurrence of ADEs. Larger, teaching, for-profit, government, and urban hospitals had higher ADE rates, which might reflect unmeasured patient complexity, differences in practice patterns, or challenges with the complexity of EHR implementation and changing organizational culture in these settings. 18 One explanation for higher ADE rates in for-profit and governmentowned hospitals could be slower uptake of medication-related EHR functionalities relative to nonprofit hospitals. 6 Nonwhite patients were more likely to have ADEs, which is consistent with some prior studies on racial disparities. 19 Although MU capabilities were significantly associated with lower occurrence of ADEs, that explained only a portion of the observed ADE decline. While consistent with prior projections on expected reductions in medication errors, 20 our calculations suggest that adoption of health IT alone does not fully explain recent declines in ADEs.
Findings from this study have important policy implications to inform initiatives to prevent ADEs and promote safer care through adoption of health IT. Since 2011, 2 nationwide initiatives have focused on reductions in ADEs and adoption of health IT. The Partnership for Patients (PfP) focuses on measurement and improvement strategies enabled by health IT, 21 while HITECH and MU incentivize adoption of health IT to reduce ADEs. PfP's work in quality improvement and learning collaboratives likely played a major role in the reduction of ADEs. However, our results support the contention Test of equality of proportions significant at ***P < .001. that adoption of MU capabilities and interoperability spurred by HITECH contributed in part to the recent decline in ADEs. Health IT and MU capabilities play a prominent role in policies to improve medication safety. Consensus guidelines for optimized inpatient anticoagulation therapy recommend the use of specific MU capabilities to prevent errors and ADEs. 22 The National Action
Plan for Adverse Drug Event Prevention (ADE Action Plan) outlines the federal government's strategy to reduce the burden of ADEs through prevention, surveillance, oversight, and research. 23 Further adoption of MU capabilities is a critical enabler of these strategies for ADE reduction. Interoperability of EHRs is an important component of health IT policies. In 2015, the Office of the National Coordinator for Health Information Technology outlined a Nationwide Interoperability Roadmap that calls for greater adoption of interoperability to share data among hospitals and providers. 24 Monitoring the adoption and impact of interoperability is necessary to achieve the roadmap's vision of a learning health system.
Limitations
Our study had several important limitations. Our estimates report associations only and cannot be interpreted as causal effects. While we adjusted for patient risk factors and key hospital characteristics, our results may be biased by confounding factors omitted from the analyses. We were unable to separate the direct effects of MU capabilities from the indirect effects of complementary strategies, such as health IT-enabled safety improvement initiatives. Our measures of ADEs and MU capabilities were limited. We were unable to examine secular trends in ADEs prior to 2010 due to changes in the MPSMS sample from Medicare fee-for-service patients to all payer patients age 18 and older starting in 2010. Small sample sizes precluded an assessment of whether each type of ADE was affected to a similar extent. MPSMS data were limited to selected medications/drug classes and did not include some important high-risk medications (eg, opioids). Since the MPSMS sample is limited to 4 medical condition groups, it is unclear whether our results are generalizable to all inpatient stays. The MPSMS hospital sample was a rotating panel, which precluded longitudinal analyses of the same hospitals over time. Our measure of MU capabilities from HIMSS data reflected hospital adoption status but did not capture MU attestation, the stepwise rollout of MU requirements, or actual use of medication-related EHR functionalities.
Finally, our study did not examine integration of systems, effectiveness of implementation and workflow changes, and optimization of safety features. These issues are important topics for future research.
CONCLUSION
We found that rates of in-hospital ADEs declined from 2010 to 2013, while adoption of MU capabilities and interoperability grew rapidly over this period. MU capabilities were associated with lower occurrences of ADEs, with the strongest relationship with interoperability. We calculated that about one-fifth of the decline in ADEs from 2010 to 2013 was attributable to MU capabilities.
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